Agios Pharmaceuticals (AGIO) Scheduled to Post Earnings on Wednesday
Agios Pharmaceuticals (NASDAQ:AGIO) is set to announce its earnings results before the market opens on Wednesday, February 14th. Analysts expect the company to announce earnings of ($1.65) per share for the quarter.
Shares of Agios Pharmaceuticals (NASDAQ:AGIO) opened at $73.11 on Monday. The firm has a market capitalization of $3,560.00, a PE ratio of -11.66 and a beta of 2.12. Agios Pharmaceuticals has a 12 month low of $45.11 and a 12 month high of $82.96.
Several analysts recently weighed in on AGIO shares. Credit Suisse Group raised their price objective on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd. Oppenheimer set a $83.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, November 17th. SunTrust Banks set a $80.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, November 19th. Cann reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, December 5th. Finally, Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 12th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $77.64.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.